Press Releases Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.458 ^USD	+5.05%		-2.24%	-56.39%

Apr. 24	Transcript : Evoke Pharma, Inc. - Special Call
Mar. 21	Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications	Apr. 17	AQ
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	Mar. 21	AQ
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 14	AQ
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	Mar. 07	AQ
Evoke Pharma Announces Closing of $7.5 Million Public Offering	Feb. 14	AQ
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	Feb. 09	AQ
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray	Nov. 30	AQ
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent	Nov. 27	AQ
Evoke Pharma : Failure to Satisfy Listing Rule - Form 8-K	Nov. 22	PU
Evoke Pharma - United States Patent and Trademark Office Grants another Formulation Patent Covering GIMOTI	Nov. 15	AQ
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI	Nov. 14	AQ
Evoke Pharma Reports Third Quarter 2023 Financial Results	Nov. 09	AQ
Evoke Pharma and EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide	Nov. 01	AQ
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023	23-10-31	AQ
Evoke Pharma's Abstract Entitled 'Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients' to Be Presented at The American College of Gastroenterology 2023	23-10-19	AQ
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting	23-10-18	AQ
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®	23-09-14	AQ
Evoke Pharma Reports Second Quarter 2023 Financial Results	23-08-10	AQ
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society Meeting	23-08-08	AQ
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting	23-08-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Press Releases

Filters